{"title":"对 \"替扎帕肽对 2 型糖尿病患者疗效的真实世界评估 \"的更正。","authors":"","doi":"10.1111/dom.16083","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Kelly, MS</span>, <span>Scopelliti, EM</span>, <span>Goodson, KE</span>, <span>Lo, CMA</span>, <span>Nguyen, HX</span>, <span>Simon, B</span>. <span>Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus</span>. <i>Diabetes Obes Metab.</i> <span>2024</span>; <span>26</span>(<span>12</span>): <span>5661</span>–<span>5668</span>. doi:10.1111/dom.15934\n </p><p>In the first paragraph of the introduction paragraph, reference #3 is cited as the “SUSTAIN trial”, which is incorrect. This should have read, “SURMOUNT-1 trial” and does reference the correct trial.</p><p>We apologize for this error.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 2","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16083","citationCount":"0","resultStr":"{\"title\":\"Correction to “Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”\",\"authors\":\"\",\"doi\":\"10.1111/dom.16083\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>\\n <span>Kelly, MS</span>, <span>Scopelliti, EM</span>, <span>Goodson, KE</span>, <span>Lo, CMA</span>, <span>Nguyen, HX</span>, <span>Simon, B</span>. <span>Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus</span>. <i>Diabetes Obes Metab.</i> <span>2024</span>; <span>26</span>(<span>12</span>): <span>5661</span>–<span>5668</span>. doi:10.1111/dom.15934\\n </p><p>In the first paragraph of the introduction paragraph, reference #3 is cited as the “SUSTAIN trial”, which is incorrect. This should have read, “SURMOUNT-1 trial” and does reference the correct trial.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"27 2\",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16083\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16083\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16083","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Correction to “Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”
Kelly, MS, Scopelliti, EM, Goodson, KE, Lo, CMA, Nguyen, HX, Simon, B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab.2024; 26(12): 5661–5668. doi:10.1111/dom.15934
In the first paragraph of the introduction paragraph, reference #3 is cited as the “SUSTAIN trial”, which is incorrect. This should have read, “SURMOUNT-1 trial” and does reference the correct trial.
期刊介绍：
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
